Medexus Pharmaceuticals Received FDA Approval for Hemophilia B Treatment, Ixinity®

Medexus Pharmaceuticals has received FDA approval for their hemophilia B treatment, Ixinity®, for children under 12. This approval, based on positive Phase 3/4 study results, allows the use of Ixinity® for prophylaxis and management of bleeding episodes in pediatric patients, offering hope for improved quality of life for affected children. Read about it here.

Source: LA Kelley Communications, Inc., May 2024